EQL Pharma
Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected
The delivery delays have also led to postponements of launches that were supposed to take place in Q2. These will instead take place towards the end of Q3 or early in Q4.
As a result of the delivery delays, EQL Pharma announces that sales in the second quarter are expected to land just under 90 (85.2) MSEK, i.e. a single-digit growth compared to the same quarter last year.
Profit is also affected, but not as significantly as sales. Here, an EBITDA margin closer to 20 than 25 percent is expected for the full year 2025/26.
The problems are of a temporary nature and do not affect the prospects of delivering on the Company's recently communicated five-year target.
All figures are preliminary and unaudited. EQL Pharma's results for the second quarter will be presented in full on Wednesday, November 5, 2025.
This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 22-09-2025 22:35 CET.
| Datum | 2025-09-22, kl 22:35 |
| Källa | Cision |
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!